FDA Clears Etcamah as First Line Oral SERD for ESR1 Mutated Breast Cancer

What changed

The U.S. FDA approved AstraZeneca's Etcamah (camizestrant) on 4 September 2026 for adults with ESR1 mutated, hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer during aromatase inhibitor and CDK4/6 inhibitor therapy. The accelerated approval requires an FDA authorized test to detect ESR1 mutations; Guardant Health's Guardant360 CDx companion diagnostic was cleared alongside the drug.

Etcamah is an oral selective estrogen receptor degrader taken at 75 mg once daily with a CDK4/6 inhibitor. It arrives after an FDA Oncologic Drugs Advisory Committee vote in May questioned SERENA 6 data strength, followed by a three month review extension. AstraZeneca has cited peak sales ambitions near five billion dollars annually for the franchise.

Why it matters

This is the first oral SERD approved as a first line switch option in this biomarker defined population, not merely a later line salvage therapy. That shifts sequencing decisions for oncologists managing ESR1 emergence on CDK4/6 backbones and ties prescribing to liquid biopsy workflows through Guardant360 CDx.

Accelerated approval inserts confirmatory risk: uptake will depend on how quickly community sites adopt ctDNA testing and how payers cover oral SERD plus CDK4/6 combinations versus existing second line oral SERDs such as Orserdu and Inluriyo.

Who is affected

Oncology formulary committees at community and academic centers. Guardant and other ctDNA vendors competing for ESR1 testing share. AstraZeneca competitors Menarini and Lilly in the oral SERD class. Payers modeling first line switch economics against later line oral SERD use.

What to do next

Map your institution's ESR1 testing pathway on progressing HR positive metastatic patients and confirm whether Guardant360 CDx is already in network before Etcamah appears on wholesaler feeds.

What to watch

Confirmatory trial readouts tied to accelerated approval obligations. Uptake data in markets where Etcamah already launched ahead of the U.S. decision, including Europe and Japan per trade reporting. Payer policy bulletins on first line oral SERD combinations.

Sources

1. Primary. Neodrop FDA ledger summary citing Drugs@FDA actions, Zanvastro and Etcamah lead the Aug. 29–Sep. 4 FDA approval ledger (September 2026). Approval date, population, companion diagnostic requirement, dosing.
2. Secondary. pharmaphorum, FDA overrides adcomm and approves AZ's oral SERD (7 September 2026). ODAC history, first line positioning, Guardant360 CDx pairing.